Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q16586
UPID:
SGCA_HUMAN
Alternative names:
50 kDa dystrophin-associated glycoprotein; Adhalin; Dystroglycan-2
Alternative UPACC:
Q16586; A6NEB8; A8K3K7; Q13710; Q13712
Background:
Alpha-sarcoglycan, also known as Adhalin or 50 kDa dystrophin-associated glycoprotein, plays a crucial role in muscle function. It is a component of the sarcoglycan complex, integral to linking the F-actin cytoskeleton with the extracellular matrix. This protein's interaction is vital for muscle integrity and function.
Therapeutic significance:
Mutations in Alpha-sarcoglycan are directly linked to Muscular dystrophy, limb-girdle, autosomal recessive 3, a condition characterized by progressive muscle wasting. Understanding the role of Alpha-sarcoglycan could lead to novel therapeutic strategies for this debilitating disease.